Optimal dosing of dihydroartemisinin-piperaquine for seasonal malaria chemoprevention in young children
Open Access
- 29 January 2019
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 10 (1) , 1-12
Abstract
Young children are the population most severely affected by Plasmodium falciparum malaria. Seasonal malaria chemoprevention (SMC) with amodiaquine and sulfadoxine-pyrimethamine provides substantial benefit to this vulnerable population, but resistance to the drugs will develop. Here, we evaluate the use of dihydroartemisinin-piperaquine as an alternative regimen in 179 children (aged 2.33–58.1 months). Allometrically scaled body weight on pharmacokinetic parameters of piperaquine result in lower drug exposures in small children after a standard mg per kg dosage. A covariate-free sigmoidal EMAX-model describes the interval to malaria re-infections satisfactorily. Population-based simulations suggest that small children would benefit from a higher dosage according to the WHO 2015 guideline. Increasing the dihydroartemisinin-piperaquine dosage and extending the dose schedule to four monthly doses result in a predicted relative reduction in malaria incidence of up to 58% during the high transmission season. The higher and extended dosing schedule to cover the high transmission period for SMC could improve the preventive efficacy substantially.Keywords
This publication has 50 references indexed in Scilit:
- A population pharmacokinetic model of piperaquine in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum malaria in SudanMalaria Journal, 2012
- Population Pharmacokinetics of Dihydroartemisinin and Piperaquine in Pregnant and Nonpregnant Women with Uncomplicated MalariaAntimicrobial Agents and Chemotherapy, 2012
- Randomized, Double-Blind, Placebo-Controlled Trial of Monthly versus Bimonthly Dihydroartemisinin-Piperaquine Chemoprevention in Adults at High Risk of MalariaAntimicrobial Agents and Chemotherapy, 2012
- A Small Amount of Fat Does Not Affect Piperaquine Exposure in Patients with MalariaAntimicrobial Agents and Chemotherapy, 2011
- Piraña and PCluster: A modeling environment and cluster infrastructure for NONMEMComputer Methods and Programs in Biomedicine, 2011
- Selection of Known Plasmodium falciparum Resistance-Mediating Polymorphisms by Artemether-Lumefantrine and Amodiaquine- Sulfadoxine-Pyrimethamine but Not Dihydroartemisinin- Piperaquine in Burkina FasoAntimicrobial Agents and Chemotherapy, 2010
- Comparison of plasma, venous and capillary blood levels of piperaquine in patients with uncomplicated falciparum malariaEuropean Journal of Clinical Pharmacology, 2010
- Humoral Responses toPlasmodium falciparumBlood-Stage Antigens and Association with Incidence of Clinical Malaria in Children Living in an Area of Seasonal Malaria Transmission in Burkina Faso, West AfricaInfection and Immunity, 2008
- Pharmacokinetics and Efficacy of Piperaquine and Chloroquine in Melanesian Children with Uncomplicated MalariaAntimicrobial Agents and Chemotherapy, 2008
- Clinical and Pharmacological Determinants of the Therapeutic Response to Dihydroartemisinin-Piperaquine for Drug-Resistant MalariaAntimicrobial Agents and Chemotherapy, 2007